Literature DB >> 19214638

Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease.

Claudia Kuntner1, Adam L Kesner, Martin Bauer, Robert Kremslehner, Thomas Wanek, Markus Mandler, Rudolf Karch, Johann Stanek, Tanja Wolf, Markus Müller, Oliver Langer.   

Abstract

PURPOSE: We evaluated the usefulness of small animal brain positron emission tomography (PET) imaging with the amyloid-beta (A beta) probe 2-(1-{6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malonitrile ([(18)F]FDDNP) and with 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) for detection and quantification of pathological changes occurring in a transgenic mouse model of Alzheimer's disease (Tg2576 mice). PROCEDURES: [(18)F]FDDNP (n = 6) and FDG-PET scans (n = 3) were recorded in Tg2576 mice (age 13-15 months) and age-matched wild-type litter mates. Brain volumes of interest were defined by co-registration of PET images with a 3D MOBY digital mouse phantom. Regional [(18)F]FDDNP retention in mouse brain was quantified in terms of the relative distribution volume (DVR) using Logan's graphical analysis with cerebellum as a reference region.
RESULTS: Except for a lower maximum brain uptake of radioactivity in transgenic animals, the regional brain kinetics as well as DVR values of [(18)F]FDDNP appeared to be similar in both groups of animals. Also for FDG, regional radioactivity retention was almost identical in the brains of transgenic and control animals.
CONCLUSIONS: We could not detect regionally increased [(18)F]FDDNP binding and regionally decreased FDG binding in the brains of Tg2576 transgenic versus wild-type mice. However, small group differences in signal might have been masked by inter-animal variability. In addition, technical limitations of the applied method (partial volume effect, spatial resolution) for measurements in such small organs as mouse brain have to be taken into consideration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19214638     DOI: 10.1007/s11307-009-0198-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  22 in total

1.  PET of brain amyloid and tau in mild cognitive impairment.

Authors:  Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

Review 2.  Drug discovery in dementia: the role of rodent models.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Nat Rev Drug Discov       Date:  2006-11       Impact factor: 84.694

3.  Expression patterns of developmental control genes in normal and Engrailed-1 mutant mouse spinal cord reveal early diversity in developing interneurons.

Authors:  M P Matise; A L Joyner
Journal:  J Neurosci       Date:  1997-10-15       Impact factor: 6.167

Review 4.  Amyloid imaging in Alzheimer's disease.

Authors:  Agneta Nordberg
Journal:  Curr Opin Neurol       Date:  2007-08       Impact factor: 5.710

Review 5.  Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease.

Authors:  Ian Churcher; Dirk Beher
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

6.  PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.

Authors:  Hiroshi Toyama; Daniel Ye; Masanori Ichise; Jeih-San Liow; Lisheng Cai; David Jacobowitz; John L Musachio; Jinsoo Hong; Mathew Crescenzo; Dnyanesh Tipre; Jian-Qiang Lu; Sami Zoghbi; Douglass C Vines; Jurgen Seidel; Kazuhiro Katada; Michael V Green; Victor W Pike; Robert M Cohen; Robert B Innis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-25       Impact factor: 9.236

7.  High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP) ready for animal or human administration.

Authors:  Jie Liu; Vladimir Kepe; Alenka Zabjek; Andrej Petric; Henry C Padgett; Nagichettiar Satyamurthy; Jorge R Barrio
Journal:  Mol Imaging Biol       Date:  2007 Jan-Feb       Impact factor: 3.488

8.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

Authors:  Kooresh Shoghi-Jadid; Gary W Small; Eric D Agdeppa; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Stephen Read; Nagichettiar Satyamurthy; Andrej Petric; Sung-Cheng Huang; Jorge R Barrio
Journal:  Am J Geriatr Psychiatry       Date:  2002 Jan-Feb       Impact factor: 4.105

9.  Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers.

Authors:  Liang Ye; Jennifer L Morgenstern; Jonathan R Lamb; Andrew Lockhart
Journal:  Biochem Biophys Res Commun       Date:  2006-06-30       Impact factor: 3.575

10.  Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography.

Authors:  Jun Maeda; Bin Ji; Toshiaki Irie; Takami Tomiyama; Masahiro Maruyama; Takashi Okauchi; Matthias Staufenbiel; Nobuhisa Iwata; Maiko Ono; Takaomi C Saido; Kazutoshi Suzuki; Hiroshi Mori; Makoto Higuchi; Tetsuya Suhara
Journal:  J Neurosci       Date:  2007-10-10       Impact factor: 6.167

View more
  39 in total

1.  Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease.

Authors:  Géraldine Poisnel; Anne-Sophie Hérard; Nadine El Tannir El Tayara; Emmanuel Bourrin; Andreas Volk; Frank Kober; Benoit Delatour; Thierry Delzescaux; Thomas Debeir; Thomas Rooney; Jésus Benavides; Philippe Hantraye; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2011-11-12       Impact factor: 4.673

2.  Synthesis and evaluation of (13)N-labelled azo compounds for β-amyloid imaging in mice.

Authors:  Vijay Gaja; Vanessa Gómez-Vallejo; Maria Puigivila; Carlos Pérez-Campaña; Abraham Martin; Ana García-Osta; Teresa Calvo-Fernández; Mar Cuadrado-Tejedor; Rafael Franco; Jordi Llop
Journal:  Mol Imaging Biol       Date:  2013-12-06       Impact factor: 3.488

3.  Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease.

Authors:  Ai-Ling Lin; Wei Zheng; Jonathan J Halloran; Raquel R Burbank; Stacy A Hussong; Matthew J Hart; Martin Javors; Yen-Yu Ian Shih; Eric Muir; Rene Solano Fonseca; Randy Strong; Arlan G Richardson; James D Lechleiter; Peter T Fox; Veronica Galvan
Journal:  J Cereb Blood Flow Metab       Date:  2013-06-26       Impact factor: 6.200

4.  [F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment.

Authors:  Edmond Teng; Vladimir Kepe; Sally A Frautschy; Jie Liu; Nagichettiar Satyamurthy; Fusheng Yang; Ping-Ping Chen; Graham B Cole; Mychica R Jones; Sung-Cheng Huang; Dorothy G Flood; Stephen P Trusko; Gary W Small; Gregory M Cole; Jorge R Barrio
Journal:  Neurobiol Dis       Date:  2011-05-13       Impact factor: 5.996

5.  Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease.

Authors:  Xueli Zhang; Yanli Tian; Can Zhang; Xiaoyu Tian; Alana W Ross; Robert D Moir; Hongbin Sun; Rudolph E Tanzi; Anna Moore; Chongzhao Ran
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-21       Impact factor: 11.205

6.  Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models.

Authors:  Rachel M Nicholson; Yael Kusne; Lee A Nowak; Frank M LaFerla; Eric M Reiman; Jon Valla
Journal:  Brain Res       Date:  2010-08-06       Impact factor: 3.252

7.  Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease.

Authors:  Xueli Zhang; Yanli Tian; Zeng Li; Xiaoyu Tian; Hongbin Sun; Hong Liu; Anna Moore; Chongzhao Ran
Journal:  J Am Chem Soc       Date:  2013-10-25       Impact factor: 15.419

8.  Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion.

Authors:  Florian C Maier; Hans F Wehrl; Andreas M Schmid; Julia G Mannheim; Stefan Wiehr; Chommanad Lerdkrai; Carsten Calaminus; Anke Stahlschmidt; Lan Ye; Michael Burnet; Detlef Stiller; Osama Sabri; Gerald Reischl; Mathias Staufenbiel; Olga Garaschuk; Mathias Jucker; Bernd J Pichler
Journal:  Nat Med       Date:  2014-11-10       Impact factor: 53.440

9.  Iterative Image Processing for Early Diagnostic of Beta-Amyloid Plaque Deposition in Pre-Clinical Alzheimer's Disease Studies.

Authors:  Nikolai V Slavine; Padmakar V Kulkarni; Roderick W McColl
Journal:  J Appl Bioinforma Comput Biol       Date:  2017-05-31

10.  In vivo imaging biomarkers in mouse models of Alzheimer's disease: are we lost in translation or breaking through?

Authors:  Benoît Delatour; Stéphane Epelbaum; Alexandra Petiet; Marc Dhenain
Journal:  Int J Alzheimers Dis       Date:  2010-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.